Crossmark

Treatment of Patients with Advanced Gastroesophageal Adenocarcinoma: Does Age Matter?

Crossref DOI link: https://doi.org/10.1007/s40266-019-00638-z

Published Online: 2019-01-25

Published Print: 2019-05

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Lorenzen, Sylvie

Hofheinz, Ralf-Dieter
License Information

Text and Data Mining valid from 2019-01-25
More Information

Article History

First Online: 25 January 2019

Compliance with Ethical Standards

:

: No external funding was used in the preparation of this manuscript.

: Sylvie Lorenzen has received honoraria from Amgen, Bristol-Myers-Squibb, Merck, MSD, Lilly, Roche Pharma, and Servier, and has served as an advisor for Bristol-Myers-Squibb, Merck, MSD, Lilly, Roche Pharma, and Sanofi Aventis. Ralf-Dieter Hofheinz has received honoraria from Amgen, Boehringer Ingelheim, Bristol-Myers-Squibb, Merck, MSD, Lilly, Roche Pharma, Medac, Servier, and Sanofi, and has served as an advisor for Merck, Lilly, Roche Pharma, Sanofi Aventis, Amgen, and Bristol-Myers-Squibb. His institution has received research funding from Sanofi Aventis, Merck, and Amgen.